Methylphenidate Analogues for Alpha-Synuclein Aggregation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease, such as methylphenidate (MPH), do not effectively address alpha-synuclein aggregation and synaptic impairment, which contribute to motor deficits and neuronal degeneration in Parkinson's disease.
Innovation Solution
Development of methylphenidate analogues, particularly the threo isomer (I-threo), which modulate the interaction between alpha-synuclein and Synapsin III, reducing aggregation and enhancing functional interaction to stimulate motor activity and protect nigrostriatal neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If methylphenidate (MPH) is used to treat Parkinson's disease, then motor symptoms are improved, but alpha-synuclein aggregation is not adequately addressed
Solution Approach 1:
The patent modifies the chemical structure of methylphenidate by changing stereochemical parameters (threo vs erythro isomers) and substituent parameters (different R groups at positions 1, 2, and 3) to create analogues with enhanced ability to address alpha-synuclein aggregation while maintaining motor symptom improvement
Solution Approach 2:
The patent introduces specific local modifications to the MPH molecule, such as placing methyl groups at specific positions (R1=Me, R2=H or R1=H, R2=Me) and using specific stereochemistry (threo isomer), to create regions of the molecule that specifically target alpha-synuclein/Synapsin III interplay while maintaining overall dopaminergic activity
2Reliability
If MPH analogues are developed to target alpha-synuclein/Synapsin III interplay, then disease-modifying effects are achieved, but compound complexity increases
Solution Approach 1:
The patent segments the modification strategy into discrete positional parameters (R1, R2, R3 positions on the molecule) and stereochemical segments (threo vs erythro), allowing systematic exploration of structure-activity relationships to find the minimal complexity required for disease-modifying effects
Solution Approach 2:
The patent systematically varies specific parameters (stereochemistry at the 2-position, substituent types at positions 1, 2, and 3) to achieve disease-modifying effects while maintaining a core MPH structure, thereby controlling complexity through focused parameter optimization rather than complete structural redesign
Data Source
AI summary
The present invention describes compounds of formula (A) for use as Parkinson's disease modifying-agents, said formula (A). Surprisingly it has been found that the compounds of the invention can significantly reduce alpha-synuclein aggregation and stimulate the functional interaction between al-pha-synuclein and Synapsin III.